MedTrace Logo

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

NCT03181386 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-06-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of a protocol which does not suspend the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions in patients with non-valvular atrial fibrillation.

Conditions

Interventions

DRUG

Rivaroxaban

Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.

DRUG

Dabigatran and Apixaban

Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.

DRUG

Warfarin

The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Denise T Hachul, PhD · Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

  • Itamara LI Neves, PhD · Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

  • Elaine M Higashi, S · Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

  • Ricardo S Neves, PhD · Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

  • Francisco CC Darrieux, PhD · Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

  • Mauricio I Scanavacca, PhD · Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-03
Primary Completion
2020-11-30
Completion
2022-02-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03181386 on ClinicalTrials.gov